Description
Anti-APCDD1 Antibody, Non-Fucosylated (BioBet-570ZP) is a humanized monoclonal IgG antibody against APCDD1. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced APCDD1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
APCDD1
Full Name
adenomatosis polyposis coli down-regulated 1
Background
This locus encodes an inhibitor of the Wnt signaling pathway. Mutations at this locus have been associated with hereditary hypotrichosis simplex. Increased expression of this gene may also be associated with colorectal carcinogenesis.
Alternative Names
APCDD1; adenomatosis polyposis coli down-regulated 1; HHS; HTS; B7323; HYPT1; DRAPC1; FP701
Gene ID
147495
UniProt ID
Q8J025
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with APCDD1 include Hypotrichosis 1 and Hypotrichosis Simplex.
Function
Negative regulator of Wnt signaling pathway. Inhibits Wnt signaling in a cell-autonomous manner and acts upstream of -catenin. It may work through the interaction with Wnt and LRP proteins. May be involved in the occurrence of colorectal tumors.
Post-translational modifications
1.N-Glycosylated 2.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn100, Asn168, and Asn319
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-570ZP
Description
The anti-APCDDl antibody are used for the immunotherapeutic treatment of malignancies including, for example, KRAS and/or APC mutated colorectal cancer and KRAS mutated pancreatic cancers.
Antibody Indication
Cancer
